TaiMed Biologics was formed on September 4, 2007 to realize the vision of creating a world-class, innovation-based biotechnology company that will satisfy the unmet medical needs of patients around the world. The company will capitalize on its tremendous intellectual, extensive expertise, and management resources to develop a strong health-care product pipeline that benefits patients, rewards investors, and propels ourselves to prominence in the biotechnology industry. The company signed an agreement with Genentech for the licensing of Ibalizumab shortly after its formation. This drug candidate, also known as TMB-355, is a proprietary humanized anti-CD4 monoclonal antibody for the treatment of HIV/AIDS.

TaiMed Biologics is committed to conducting business with integrity and passion. We remain to be forward-thinking and utilize our resources wisely and efficiently in order to meet our long-term objectives.

Founders

David Ho, M.D., Chief of TaiMed Scientific Advisor 

Director and CEO, Aaron Diamond AIDS Research Center, and Irene Diamond Professor, Rockefeller University.

Dr. Ho has been a world leading authority in AIDS research for 25 years while publishing over 350 papers. He championed combination antiretroviral therapy that has resulted in unprecedented control of HIV in patients. Among Dr. Ho’s many honors include his election to the membership of the American Academy of Arts and Sciences; Institute of Medicine, National Academy of Science in the United States; Academia Sinica (Republic of China); and Chinese Academy of Engineering. Dr. Ho also holds the rare honor of simultaneously serving on Board of Trustees of the California Institute of Technology and the Board of the Massachusetts Institute of Technology Corporation.

LanBo Chen, Ph.D., Chairman of TMB USA Inc.

Academicians of the Academia Sinica, Professor of Pathology, Emeritus, at Harvard Medical School,

Ing-Wen Tsai, Ph.D. in law from the London School of Economics and Political Science

President of Republic of China (Taiwan), Former chairperson of TaiMed Biologics.

2017

May
TaiMed Submits Biologics License Application to US FDA for Ibalizumab (TMB-355)
Mar
License agreement with ADARC for Bispecific Antibodies technology
TaiMed and Theratechnologies agreed to extend the exclusive Marketing and Distribution Agreement for Ibalizumab to Europe territory

2016

Dec
Initiated TMB-607 Phase I clinical study for HIV teatment in US
Nov
TMB-355 maintains significant reduction of viral load in patients with multi-drug resistant HIV-1 over 24 Weeks based on the results of the Phase III study-301 trial
Sep
US$ 500 thousand R&D subsidies from US FDA for the TMB-355 phase III clinical trial
Aug
Board of directors Approved to build production facility in Hsinchu Biomedical Science Park.
Jul
TMB-355 BLA (CMC section) filed to US FDA for reviewing
Mar
TaiMed and Theratechnologies signed an exclusive Marketing and Distribution Agreement for Ibalizumab in US and Canada territory

2015

Nov
Publicly listed on Taipei Exchange Market in Taiwan on 23 November, 2015
Aug
Initiated TMB-355 IV injection Phase IIII clinical study for HIV in US and Taiwan
Apr
Initiated the development for TMB-365, improved from TMB-360 by ADARC
Feb
Breakthrough therapy designated by FDA for TMB-355 IV injection

2014

Dec
Licensing of TMB-360(LM 52), the second generation of ibalizumab from TMB USA
Otc
Organ Drug status designated by US FDA for TMB-355 HIV treatment in multi-drug resistant patients
Aug
NT$ 1,497 thousand R&D subsidies from MOEA for the HIV long-acting injection development of TMB-607
Jul
Terminated the project of integrase Inhibitor (INI), licensing from Ambrilia Biopharma Inc
Apr
US FDA Approved Ibalizumab Manufactured by WuXi PharmaTech for Treatment of Patients on Expanded Access
Mar
Terminated the project of Tamiphosphor, licensing from Academia Sinica
Jan
TaiMed office and Lab relocated to Ruigang Road, Neihu Science Park

2013

Otc
The technology HIV antibody TMB-360(LM 52), the second generation of ibalizumab, published in “Nature Biotechnology” magazine
Sep
NT$ 9 million R&D subsidies from MOEA for the clinical trial of phase I/II of TMB-355 IM & SC injection

2012

Otc
Completed TMB-355 SC injection phase I clinical study for HIV in U
Jul
TaiMed and WuXiApptec signed the CMO contract for TMB-355

2011

Aug
Technology Transfer silver medal for TMB-355 project received at the 2013 Taipei Biotech Award
Jun
Completed the end of phase II meeting with US FDA for the Ibalizumab (TMB-355) IV injection clinical trial
Apr
TMB USA, 100% of TaiMed subsidiary, exclusively Licensed the Fusion Proteins technology from Rockefeller University
Mar
Exclusively licensed two HIV treatment projects from Ambrilia Biopharma Inc. one is Protease Inhibitor (PI),the other is Integrase Inhibitor (INI)

2010

Jun
Listed on Emerging Market in Taipei Exchange Market (ticker number:4147)
May
Approval for TaiMed shares retroactive handling of public issuance procedure from Securities and Futures Bureau

2009

Nov
TMB-355 prevention research subsidies from Bill & Melinda Gates Foundation
Apr
TaiMed Chinese name changed as “中裕新藥股份有限公司”

2008

Dec
Exclusively licensed Tamiphosphor project from Academia Sinica
Sep
Qualified as new drug company under the “Act for the development of Biotech and new pharmaceuticals industry” from MOEA
Jul
Established preclinical lab in the Biotech Incubation Center of Academia Sinica
May
Initiated TMB-355 IV injection phase IIb clinical trial
Mar
Appointed James Chang as CEO of Taimed

2007

Otc
Established TaiMed Biologics USA in Irvine, California
Sep
Board of directors elected Ing-Wen Tsai, Ph.D as the first chairperson of TaiMed
TaiMed Biologics Inc. established as a new drug development company
TaiMed and Genentech signed an exclusive license agreement for anti-cd4 antibody known as Ibalizumab (TMB-355)